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Summary 
Supersensitivity of a muscarinic mechanism is implicated in 
the pathophysiology of depression. Bright artificial light is 
efficacious in the treatment of Seasonal Affective Disorder (SAD). 
We studied the effect of constant bright light (11,500 lux) on the 
sensitivity of adult, male rats to oxotremorine, 1.5 mg/kg ip, 
using a repeated measures design. Oxotremorine challenges were 
proceeded by the injection of methylscopolamine, 1 mg/kg ip, by 70 
minutes. Temperature was telemetrically measured every 10 minutes 
for 120 minutes starting 10 minutes after the injection of 
oxotremorine. Prior to and after 7 continuous days of exposure to 
bright light, the sample exhibited a hypothermic response of 2.50 + 
0.4R"C (mean + SEM) and 0.29 + 0.31"C (mean + SEM), respectively - 
(p < 0.0014)._ All 7 animals exhibited blunting to the thermic 
response to oxotremorine. Bright light also blocked the capacity 
of amitriptyline to supersensitize a central muscarinic mechanism. 
Exposure to light at an intensity of 300 lux for 7 days had no 
effect on the thermic response to oxotremorine. These data are 
consistent with the hypotheses that the biology of depression 
involves supersensitivity of central muscarinic mechanisms and that 
the effects of bright artificial light are not the consequence of 
shifting circadian rhythms. 
Seasonal Affective Disorder (SAD) is a syndrome characterized by 
recurrent depressions which occur annually (1). This syndrome responds to 
daily treatment with 2-6 hours of bright artificial light (l-5). A 
mechanism accounting for the efficacy of this treatment has not been 
identified. Certain forms of affective disorders may involve state 
independent supersensitivity of central cholinergic systems (6). Data 
supporting a cholinergic hypothesis of depression were recently summarized 
(7-8). This article presents data indicating that bright artificial light 
blunts the hypothermic response to oxotremorine and prevents the 
supersensitization of muscarinic mechanisms produced by a muscarinic 
receptor antagonist (9). 
Materials and Methods 
The dependent variable in the experiments reported here was change in 
core temperature in response to a muscarinic agonist, oxotremorine. Core 
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temperature was measured using a telemetric thermosensor, the Model VM 
Mini-Mitter (Mini-Mitter Corp., Sun River, OR). These devices emit radio 
waves at a frequency which is detectable using an AiY receiver. Information 
regarding the calibration, reliahility and validity of the Mini-Mitter is 
available elsewhere (10). 
All oxotremorine challenges started at between 0900 and 1000 on the 
first and eighth days of Experiment 1 and on the first, eighth and fifteenth 
days of Experiments 2 and 7. Challenges occurred 20 hours after the 
fourteenth and twenty-eighth doses of amitriptyline (AMI) in Experiments 2 
and 7. 
Amitriptyline (AMI) hydrochloride and oxotremorine (base) was purchased 
from Sigma Chemical Co. (St. Louis, MO). 
Full-spectrum bright artificial light (11,500 lux) was emitted from a 
bank of 8 122 cm long Vitalight tubes suspended 50 cm above the animals. 
This light unit (Duro Test Co., Bergen, NJ, Model 5599) is used to treat 
patients with SAD (2). Temperature under the lights was 23°C. 
Experiment 1: Mini-Mitters were implanted into the peritoneal cavities 
of 7 adult, male Sprague Dawley rats (mean weight + SEM = 219.7 + 9.2 g). 
Experiment 1 involved measurement of the hypothermic response to- 
oxotremorine, 1.5 m&kg ip, prior to exposure to bright artificial light 
(baseline), after one week of constant light exposure, and one week after 
the withdrawal of bright artifical light. During the baseline and 
withdrawal phases the animals were subject to the standard 12 hour 
light/dark cycle. 
Methylscopolamine nitrate, 1 mg/kg ip, was administered 30 minutes prior 
to the injection of oxotremorine in order to block peripheral effects of the 
muscarinic agonist. Core temperature was measured 30 minutes after the 
injection of methylscopolamine nitrate. The dependent variehle was change 
in core temperature relative to this point in time. Oxotremorine, 1.5 mg/kg 
ip, was then administered and core temperature measured every 10 minutes for 
120 minutes. We previously reported that methylscopolamine nitrate, 1 me/kg 
ip, does not alter core temperature 70 minutes after injection, relative to 
the pre-injection baseline (11). 
Experiment 2: Mini-Mitters were implanted in the peritoneal cavities of 
8 adult, male Sprague-Dawley rats (mean weight 2 SEM = 339.5 + 12.1 g). The 
hypothermic response to oxotremorine, 1 mg/kg ip, was first measured at 
baseline (prior to any experimental manipulation). This challenge was 
immediately followed by one week of treatment with AMI, 10 mg/kg ip at 0900 
and 1700, under standard lighting conditions. The first week of treatment 
with AMI was followed by an oxotremorine challenge. At the conclusion of 
this challenge the animals were immediately treated with hright artificial 
light for 7 consecutive days. AMI, 10 mg/kg ip twice daily, was 
administered throughout this period. At the conclusion of this phase of 
light exposure, the animals were rechallenged with oxotremorine (while still 
under the lights). Finally, the animals were returned to standard vivarium 
conditions. Treatment with AM1 continued. A fourth oxotremorine challenge 
was conducted 7 days later. 
Experiment 7: Mini-Mitters were implanted into the peritonealcavities 
of 10 adult, male Sprague Dawley rats (mean weight + SEM = 227 L 6.3). The 
hypothermic response to oxotremorine, 1 mg/kg ip, was measured at baseline. 
This was followed by one week of treatment with AMI, 10 m&kg ip, twice 
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daily under standard lighting conditions. The first week of treatment 
AM1 was followed by an oxotremorine challenge. The animals were then 
treated with normal flourescent light at an intensity of 300 lux for 7 
with 
consecutive days. AMI, 10 mg/kg twice daily, was administered throughout 
this period. At the conclusion of this, the second week of AM1 
administration, the animals were rechallenged with oxotremorine while they 
continued to be exposed to light at an intensity of 300 lux. 
The authors previously established that AMI, 10 mg/kg ip twice daily, 
produces supersensitivity of a central muscarinic mechanism (11). The 
capacity of this agent to do thmlays dose-dependence (12). Thus, 
demonstration that bright artificial light prevents the development of 
supersensitivity to oxotremorine would indicate that it is a potent 
inhibitor of the development of supersensitivity of a central muscarinic 
mechanism. 
Significance of change in the thermic responsiveness of each individual 
animal between weeks was measured using the Student's paired t-test. This 
was possible because the core temperature of each animal was measured 12 
times after the injection of oxotremorine. Significance of the mean change 
in core temperature between points in time for each sample was also 
determined using the paired t-test. All measures of variance in the text 
refer to the standard error of the mean (SEM). 
Results 
Experiment 1: Mean core temperature was 37.5 + 0.29'C prior to the 
first challenge with oxotremorine. Mean core temperature was 37.8 + 0.3O"C 
in the presence of bright light following one week of exposure to bright 
artificial light (p > 0.15, t = 1.64, df = 6). Table 1 summarizes the mean 
thermic response over the 12 time points for all 7 animals. Six (6) animals 
demonstrated significant blunting of the hypothermic response to 
oxotremorine (1.5 mg/kg ip) at 0~ < 0.0001 after light treatment. Further, 
the mean hypothermic response of the sample, -2.46 + 0.41-C prior to light 
treatment and -0.36 + 0.3l"C afterwards, was significantly blunted after 
chronic light exposure (p < 0.0007, t = 6.50, df = 6). One week after the 
discontinuation of light treatment the mean hypothermic response of the 
sample increased to -3.14 L 0.23"C (p < 0.00009, t = 6.16, df = 6). 
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TABLE I 
A B C 
Mean Probability Based 
Mean Hypothermic on Paired t-test 
Hypothermic Response After 
Response at One Week of A vs R 
Animal # Baseline Light Treatment P< 
1 -1.93 + 0.33 -0.41 + 0.17 0.00003 - - 
2 -2.85 + 0.44 -0.24 + 0.17 0.00004 - 
3 -1.55 + 0.39 -1.11 + 0.17 n.s. - 
4 -2.98 + 0.39 -0.45 + 0.11 0.000001 - 
5 -4.04 + 0.75 -1.27 + 0.20 0 .OOOl - 
6 -0.82 + 0.34 +1.28 + 0.20 0.000005 - - 
7 -3.07 + 0.40 -0.33 + 0.46 0.000004 - - 
-2.46 + 0.41 -0.36 + 0.31 0.0007 - - 
The hypothermic response of individual animals (n = 7) to oxotremorine 
(1.5 mg/kg ip) at baseline (pretreatment) and after 7 days of 11,500 lux 
light treatment. 
Experiment 2: The mean core temperature of the sample prior to the 
first oxotremorine challenge was 37.6 - 0.13"C. Mean core temperature was 
also 36.6 + 0.24"C in the presence of bright light following one week of 
phototherapy (p = 1, t = 0, df = 7). Table 2 summarizes the mean thermic 
response for each individual animal for the three phases of the experiment 
(baseline, treatment with AIU, and concurrent treatment with AM1 and bright 
light). 
The sample exhibited a significant hypothermic response to oxotremorine, 
1.0 mg/kg ip, of -1.19 + 0.12"C at baseline (p < 0.00003, t = 9.93, df = 
7). Following one week-of treatment with ANI, 4 animals exhibited 
supersensitivity to oxotremorine at a< 0.02. Further, this treatment 
increased the sample's hypothermic response to -1.68 + 0.21-C (p < O.C4, t = 
2.55, df = 7). 
- 
All 8 animals exhibited a reduction in their hypothermic response 
relative to baseline, after one week of treatment with hoth ANI and bright 
light (p = 0.0039, sign test). Six (6) of 8 animals exhibited significant 
blunting of their hypothermic responses at Cc< 0.002 and another animal 
demonstrated a trend towards significance. The difference in the mean 
responses to oxotremorine at baseline (-1.19 + 0.12-C) and after concurrent 
treatment with AM1 and light (-0.22 _ + 0.25"C)-was highly significant (p < 
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All 8 animals demonstrated significant blunting of the hypothermic 
response to oxotremorine at cx CO.04 after concurrent treatment with AM1 
and light (sample mean + SEM = -0.22 + 0.23"C) relative to the AM1 phase 
(-1.68 + 0.21'C). The difference in the mean response to oxotremorine under 
these c%ditions was highly significant (p < 0.0015, t = 5.39, df = 7). 
Bright artificial light was discontinued after two weeks, but treatment 
with AM1 continued for another 7 days. The mean hypothermic response to 
oxotremorine 7 days after light treatment ceased was -2.03 + 0.15"C. This 
was significantly greater than the mean response during concurrent AM1 and 
light administration (p < 0.0015, t = 5.10, df = 7). 
Experiment 3: The mean core temperature of the sample prior to 
challenge with oxotremorine was 38.0 + .3"C. The sample exhibited a 
hypothermic response to oxotremorine,-1.0 mg/kg ip, of -1.6 + .3 at baseline 
(p < 0.0001, t = 6.34, df = 9). Treatment with AM1 produced-an increase in 
hypothermic response of the sample to -2.1 + .3 (p < 0.07, t = 2.05, df = 
9). The mean hypothermic response to oxotr%morine following one week of 
exposure to 300 lux light was -3.1 + .3"C. This differed from baseline (p > 
0.03, t = 2.68, df = 9). 
- 
Discussion 
Chronic treatment with bright artificial light (11,500 lux) blocked the 
capacity of AM1 to produce supersensitivity to the hypothermic effects of 
oxotremorine. However, treatment with standard fluorescent light at an 
intensity of 300 lux did not have this effect. This suggests that light 
intensity is a critical variable. Further, this observation argues against 
the hypothesis that the effects we measured result from alteration in the 
circadian rhythms consequent to constant light exposure. The intensity of 
light in the rats' cages in our vivarium is 300 lux. Sprague-Dawley rats 
demonstrate clear-cut circadian changes in motor activity and core 
temperature in response to turning the lights in the vivarium on or off. We 
therefore propose the results presented in this article are due to the 
effects of bright artificial light rather than light itself. 
Bright light (as opposed to light at an intensity of 300 lux) can have 
dramatic effects on the amplitude of circadian rhythms. This is certainly 
true of the circadian temperature rhythm. The simplist means for assessing 
whether bright artifical light altered the amplitude of the diurnal 
temperature rhythm is to determine whether mean core temperature measured at 
the same time of the day, differed prior to and at the conclusion of 
treatment with bright light. Bright artificial light was not associated 
with a change in core temperature in either Experiment 1 or 2. This could 
be the conseauence of chance. However, it is possible the cues in the 
environment entrained the animals so that the amplitude of the circadian 
temperature rhythm was preserved. For example, human activity around the 
animals might have served as an external cue allowing them to maintain the 
typical diurnal temperature amplitude or rhythm. 
The hypothermic response to oxotremorine at baseline differ considerably 
in Experiments 1 (-2.46 + 0.41) and 2 (-1.19 + 0.12-C). This is partially 
due to the use of a higher dose of oxotremorine in the first, 1.5 mg/kg ip, 
as opposed to the second. However, this point aside, one must consider that 
there is a great deal of variance in the responsiveness of Sprague-Dawley 
rats to muscarinic agonists (13). This variability of responsivity is 
simply the consequence of using an outbred line of rats. Secondly, our dose 
of AM1 merits comment since it is, on a milligram per kilogram basis, 2.5-10 
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times that administered to depressed patients. Doses of antidepressants 
(e.g., ANT, desipramine, amoxapine and fluoxetine) in the range of 10 me/kg 
ip twice daily are commonly used on a chronic basis in preclinicsl studies 
using rats without ill effect (11,12,14,15). The animals thrive, gain 
weight and exhibit no signs of toxicity on these seemingly high doses. 
Patients with SAD are typically treated with full-spectrum light at an 
intensity of 2,500 lux. There are advantages to using higher intensities of 
bright artificial light in preliminary studies. Our objective was to 
determine whether bright light, as opposed to standard room lighting, 
produces subsensitivity to the hypothermic effects of oxotremorine. Use of 
a high "dose" decreases the probability of accepting a false null hypothesis 
("hriaht artificial light does not produce subsensitivity to the thermic 
effects of oxotremorine"). !Jow that it has been demonstrated that treatment 
with full-spectrum light at an intensity of 11,500 lux results in decreased 
sensitivity to oxotrenorine, and by implication subsensitivity of nuscarinic 
receptors, it would he reasonable to evaluate lower "doses" end the effects 
of administering light for circumscribed periods of time each day. These 
studies are now under way. 
The light unit we used delivers light at an intensity of 2,500 lux at a 
distance of 172 cm from a patient's face. However, to deliver light at an 
intensity of 11,500 lux, the unit was suspended 50 cm above the animals. 
When placed this distance from the face of a patient, there is no 
discomfort. Thus, it would he feasible to change the current treatment 
protocols should studies suggest an intensity of light in excess of 2,500 
lux might be superior. 
The data presented in this article indicate that bright artificial light 
(of the variety used to treat SAD) potently produces subsensitivity of a 
central muscarinic mechanism involved in the regulation of core 
temperature. Experiment 3 indicates that the findings are not a nonspecific 
consequence of upsetting circadian rhythms due to constant light exposure. 
Finally, these results are in complete accord with the cholinergic 
hypothesis of depression. 
Janowsky et al. (16) proposed that depressive disorders are related to a 
defect in central cholinergic mechanisms. Specifically, the depressed state 
is characterized by cholinergic overdrive (7-9). Sitaram et al. (14) 
observed that euthymic ‘affective disorder patients exhihit accelerated onset 
of REM sleep in response to cholinomimetic challenge relative to normal 
subjects. This indicates that at least some forms of affective illness 
involve state independent supersensitivity of a central nuscarinic mechanism. 
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